IPHA

Innate Pharma S.A.

Price Chart

Latest Quote

$1.75

-0.02 (-1.41%)

Current Price

Previous Close	$1.77
Open	$1.72
Day High	$1.75
Day Low	$1.72
Volume	10,425

Fetched: 2026-07-18T03:30:32

Stock Information

Note: Financial values converted from EUR to USD

Shares Outstanding	93.90M
Total Debt	$25.84M
Cash Equivalents	$39.27M
Revenue	$10.31M
Net Income	$-56.29M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$164.33M
EPS (TTM)	$-0.63
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$152.40M
Sales	$10.31M
Income	$-56.29M
Book/sh	$-0.26
Cash/sh	$0.37
Employees	164

Financial Ratios

Quick Ratio	1.14
Current Ratio	1.27

Returns & Margins

ROA	-38.85%
Operating Margin	-689.55%

Ownership

Insider Ownership	1.67%
Institutional Ownership	0.45%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.76
P/S	18.25
P/B	-6.61

Analyst Data

Recommendation	none
Target Price	$6.00

Technical Indicators

SMA20	$1.82
SMA50	$1.78
SMA200	$1.75
RSI	44.54
ATR	0.0860

Shares Float	70.54M
Short Float	0.19%
Short Ratio	4.70
Volatility	0.88
Rel Volume	1.15

Performance History

Week	-2.40%
Month	-2.23%
Quarter	+8.02%
6 Months	-0.17%
YTD	-3.85%
Year	-2.78%
3 Years	-43.91%
5 Years	-47.13%
10 Years	-71.07%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$1.75	10,425
2026-07-16	$1.77	5,100
2026-07-15	$1.80	3,100
2026-07-14	$1.79	4,900
2026-07-13	$1.79	12,000
2026-07-10	$1.79	11,800
2026-07-09	$1.79	2,300
2026-07-08	$1.84	5,400
2026-07-07	$1.90	10,100
2026-07-06	$1.87	9,000
2026-07-02	$1.80	6,000
2026-07-01	$1.81	8,000
2026-06-30	$1.84	9,900
2026-06-29	$1.80	31,800
2026-06-26	$1.79	10,500
2026-06-25	$1.79	6,900
2026-06-24	$1.90	11,800
2026-06-23	$1.89	11,700
2026-06-22	$1.81	8,700
2026-06-18	$1.81	1,700

About Innate Pharma S.A.

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

📰 Latest News

Innate Pharma Q1 Earnings Call Highlights

MarketBeat • 2026-05-13T16:07:22Z

How Innate Pharma (ENXTPA:IPH) Story Is Shifting Around 2026 Catalysts And €8 Target

Simply Wall St. • 2026-03-27T06:06:39Z

Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com • 2026-03-26T19:00:56Z

Innate Pharma Q4 Earnings Call Highlights

MarketBeat • 2026-03-26T15:08:16Z

Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy

MT Newswires • 2025-11-10T09:45:58Z

Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Zacks • 2025-11-06T14:55:02Z

How the Narrative Around Innate Pharma Is Shifting After Recent Strategic Decisions

Simply Wall St. • 2025-09-20T12:21:56Z

Target initiated, Nike upgraded: Wall Street's top analyst calls

The Fly • 2025-09-18T13:38:40Z

Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial ...

GuruFocus.com • 2025-09-18T07:00:54Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$3,189,152	$14,442,156	$59,390,091	$56,734,181
Operating Revenue	$2,615,860	$14,378,075	$59,377,504	$57,440,211
Expenses
Interest Expense	$503,490	$647,671	$732,349	$329,557
Total Expenses	$64,323,150	$73,460,351	$73,887,173	$75,529,238
Other Income Expense	$3,855,132	$265,477	$2,931,686	$-47,837,282
Net Non Operating Interest Income Expense	$1,004,692	$2,140,977	$2,903,078	$295,228
Interest Expense Non Operating	$503,490	$647,671	$732,349	$329,557
Operating Expense	$64,323,150	$73,460,351	$73,887,173	$75,529,238
Other Operating Expenses	$1,822,863	$324,980	$-3,661,746	$-149,903
General And Administrative Expense	$12,586,108	$13,654,881	$13,443,186	$16,561,392
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-56,273,030	$-56,609,453	$-8,662,318	$-66,337,110
Net Interest Income	$1,004,692	$2,140,977	$2,903,078	$295,228
Interest Income	$1,508,182	$2,788,649	$3,635,427	$624,785
Normalized Income	$-60,128,162	$-56,874,929	$-11,594,004	$-18,499,829
Net Income From Continuing And Discontinued Operation	$-56,273,030	$-56,609,453	$-8,662,318	$-66,487,013
Total Operating Income As Reported	$-61,801,122	$-59,017,051	$-14,497,082	$-65,711,181
Net Income Common Stockholders	$-56,273,030	$-56,609,453	$-8,662,318	$-66,487,013
Net Income	$-56,273,030	$-56,609,453	$-8,662,318	$-66,487,013
Net Income Including Noncontrolling Interests	$-56,273,030	$-56,609,453	$-8,662,318	$-66,487,013
Net Income Discontinuous Operations	$0	$0	$0	$-149,903
Net Income Continuous Operations	$-56,273,030	$-56,609,453	$-8,662,318	$-66,337,110
Pretax Income	$-56,273,030	$-56,609,453	$-8,662,318	$-66,337,110
Special Income Charges	$-667,124	$0	$0	$-46,916,124
Interest Income Non Operating	$1,508,182	$2,788,649	$3,635,427	$624,785
Operating Income	$-61,133,998	$-59,018,195	$-14,497,082	$-18,795,057
Per Share
Diluted EPS	$-0.63	$-0.70	$-0.10	$-0.84
Basic EPS	$-0.63	$-0.70	$-0.10	$-0.84
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-53,799,062	$-53,945,532	$-9,277,950	$33,786,475
Total Unusual Items	$3,855,132	$265,477	$2,931,686	$-47,837,282
Total Unusual Items Excluding Goodwill	$3,855,132	$265,477	$2,931,686	$-47,837,282
Reconciled Depreciation	$5,825,609	$2,281,726	$1,583,705	$51,956,746
EBITDA (Bullshit earnings)	$-49,943,930	$-53,680,056	$-6,346,264	$-14,050,807
EBIT	$-55,769,540	$-55,961,781	$-7,929,969	$-66,007,553
Diluted Average Shares	$102,518,596	$92,747,455	$96,247,983	$91,131,710
Basic Average Shares	$102,518,596	$92,747,455	$96,247,983	$91,131,710
Diluted NI Availto Com Stockholders	$-56,273,030	$-56,609,453	$-8,662,318	$-66,487,013
Tax Provision	$0	$0	$0	$0
Impairment Of Capital Assets	$0	$0	$0	$46,916,124
Restructuring And Mergern Acquisition	$667,124	-	-	-
Gain On Sale Of Security	$4,522,257	$265,477	$2,931,686	$-921,158
Research And Development	$49,914,178	$59,480,490	$64,105,734	$59,117,749
Selling General And Administration	$12,586,108	$13,654,881	$13,443,186	$16,561,392
Other Gand A	$3,482,092	$3,864,287	$3,325,323	$4,856,391
Salaries And Wages	$9,104,017	$9,790,594	$10,117,863	$11,705,001

Fetched: 2026-07-17

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-24,835,794	$10,108,708	$58,914,064	$60,187,665
Total Assets	$71,769,082	$127,084,336	$200,465,731	$228,052,412
Total Non Current Assets	$18,319,030	$28,970,134	$31,096,236	$68,045,544
Other Non Current Assets	$1,083,648	$657,970	$99,554	$173,933
Non Current Accounts Receivable	$287,218	$10,673,990	$12,076,897	$16,133,425
Investmentin Financial Assets	$11,963,612	$11,764,504	$11,209,521	$40,186,521
Financial Assets Designatedas Fair Value Through Profitor Loss Total	$11,963,612	$11,764,504	$11,209,521	$40,186,521
Goodwill And Other Intangible Assets	$0	$0	$476,027	$1,777,091
Current Assets	$53,450,052	$98,114,202	$169,370,639	$160,008,012
Other Current Assets	$1,144	-	$1,144	$2,289
Prepaid Assets	$5,480,032	$3,809,360	$10,375,329	$8,380,822
Receivables	$8,708,090	$1,880,078	$53,197,163	$35,496,053
Other Receivables	$133,883	$101,842	$119,007	$69,802
Taxes Receivable	$8,126,788	$1,034,443	$35,647,100	$31,901,820
Accounts Receivable	$447,420	$743,792	$17,431,056	$3,524,431
Cash Cash Equivalents And Short Term Investments	$39,260,785	$92,424,764	$105,797,003	$116,128,849
Cash And Cash Equivalents	$32,145,555	$75,976,657	$80,792,998	$96,378,305
Non Current Deferred Assets	-	-	$10,305,527	$9,804,326
Non Current Deferred Taxes Assets	-	-	$10,305,527	$9,804,326
Other Intangible Assets	-	-	$476,027	$1,777,091
Debt
Total Debt	$25,830,187	$35,467,445	$45,649,388	$48,347,638
Long Term Debt And Capital Lease Obligation	$15,758,096	$25,501,774	$35,423,962	$45,942,328
Long Term Debt	$15,647,099	$25,382,767	$35,023,458	$44,546,287
Current Debt And Capital Lease Obligation	$10,072,091	$9,965,671	$10,225,426	$2,405,310
Current Debt	$9,743,678	$9,655,567	$9,670,443	$1,462,410
Other Current Borrowings	$9,743,678	$9,655,567	$9,670,443	$1,462,410
Liabilities
Total Liabilities Net Minority Interest	$96,604,876	$116,975,628	$141,075,640	$166,087,655
Total Non Current Liabilities Net Minority Interest	$54,667,583	$79,234,467	$95,720,335	$118,784,759
Other Non Current Liabilities	$36,329,100	$47,062,594	$51,528,780	$60,633,941
Non Current Deferred Liabilities	$0	$3,232,635	$5,284,358	$9,063,966
Current Liabilities	$41,937,293	$37,741,161	$45,355,304	$47,302,896
Other Current Liabilities	$7,439,066	$8,516,993	$8,749,285	$11,698,135
Current Deferred Liabilities	$3,232,635	$704,886	$6,711,294	$7,506,580
Payables And Accrued Expenses	$17,212,496	$18,316,741	$19,473,624	$23,928,367
Payables	$17,212,496	$18,316,741	$19,473,624	$23,928,367
Other Payable	$1,168,326	$1,283,900	$1,643,209	$1,461,266
Total Tax Payable	$7,490,560	$7,966,587	$8,034,100	$6,840,600
Accounts Payable	$8,553,610	$9,066,255	$9,796,315	$15,626,502
Non Current Deferred Taxes Liabilities	-	-	$10,305,527	$9,804,326
Equity
Common Stock Equity	$-24,835,794	$10,108,708	$59,390,091	$61,964,756
Total Equity Gross Minority Interest	$-24,835,794	$10,108,708	$59,390,091	$61,964,756
Stockholders Equity	$-24,835,794	$10,108,708	$59,390,091	$61,964,756
Gains Losses Not Affecting Retained Earnings	$1,279,323	$30,896	$566,426	$937,178
Other Equity Adjustments	$1,279,323	$30,896	$566,426	$937,178
Retained Earnings	$-498,388,838	$-442,114,664	$-385,505,211	$-377,979,178
Other Equity Interest	-	-	-	-
Other
Treasury Shares Number	$21,255	$21,255	$21,255	-
Ordinary Shares Number	$107,221,363	$95,905,438	$92,507,139	$91,020,286
Share Issued	$107,242,618	$95,926,693	$92,528,395	$91,020,286
Tangible Book Value	$-24,835,794	$10,108,708	$58,914,064	$60,187,665
Invested Capital	$554,983	$45,147,043	$104,083,993	$107,973,454
Working Capital	$11,512,759	$60,373,041	$124,015,335	$112,705,116
Capital Lease Obligations	$439,410	$429,111	$955,487	$2,338,940
Total Capitalization	$-9,188,694	$35,491,475	$94,413,550	$106,511,044
Additional Paid In Capital	$466,910,407	$447,395,588	$439,701,344	$434,416,987
Capital Stock	$5,363,314	$4,796,888	$4,627,532	$4,589,770
Common Stock	$5,363,314	$4,796,888	$4,627,532	$4,589,770
Employee Benefits	$2,200,481	$3,123,927	$2,793,226	$2,917,954
Non Current Pension And Other Postretirement Benefit Plans	$2,200,481	$3,123,927	$2,793,226	$2,917,954
Non Current Deferred Revenue	$0	$3,232,635	$5,284,358	$9,063,966
Long Term Capital Lease Obligation	$110,997	$119,007	$400,503	$1,396,041
Long Term Provisions	$379,906	$313,537	$690,010	$226,571
Current Deferred Revenue	$3,232,635	$704,886	$6,711,294	$7,506,580
Current Capital Lease Obligation	$328,413	$310,104	$554,983	$942,900
Current Provisions	$3,981,005	$236,869	$195,675	$1,764,504
Investments And Advances	$11,963,612	$11,764,504	$11,209,521	$40,186,521
Net PPE	$4,984,552	$5,873,670	$7,234,237	$9,774,574
Gross PPE	$4,984,552	$5,873,670	$7,234,237	$9,774,574
Construction In Progress	$0	$0	$0	$0
Other Properties	$2,729,145	$3,258,954	$3,849,411	$4,920,472
Land And Improvements	$2,255,407	$2,614,716	$3,384,827	$4,854,102
Properties	$0	$0	$0	$0
Other Short Term Investments	$7,115,231	$16,448,106	$25,004,005	$19,750,544
Leases	-	$1,452,111	$1,916,695	-

Fetched: 2026-07-17

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-39,947,363	$-8,338,483	$-60,527,521	$-23,202,884
Operating Activities
Operating Cash Flow	$-37,257,124	$-7,891,063	$-60,367,320	$-21,918,984
Cash Flow From Continuing Operating Activities	$-37,257,124	$-7,891,063	$-60,367,320	$-21,918,984
Operating Gains Losses	$352,443	$-619,064	$661,403	$-625,930
Investing Activities
Capital Expenditure	$-2,690,239	$-447,420	$-160,201	$-1,283,900
Investing Cash Flow	$23,606,820	$10,527,520	$8,340,771	$2,147,843
Cash Flow From Continuing Investing Activities	$23,606,820	$10,526,376	$8,339,627	$2,147,843
Net Other Investing Changes	$72,091	$1,144	$6,866	$-1,144
Financing Activities
Financing Cash Flow	$-2,249,685	$-6,874,929	$6,945,875	$-2,091,773
Cash Flow From Continuing Financing Activities	$-2,249,685	$-6,874,929	$6,945,875	$-2,091,773
Cash Dividends Paid	-	-	$0	$0
Issuance Of Capital Stock	-	-	-	-
Net Other Financing Charges	-	-	-	-
Net Common Stock Issuance	-	-	-	-
Common Stock Issuance	-	-	-	-
Other
Repayment Of Debt	$-2,701,682	$-10,225,426	$-10,196,819	$-2,318,343
End Cash Position	$80,792,998	$75,976,657	$32,145,555	$96,378,305
Beginning Cash Position	$96,378,305	$80,792,998	$75,976,657	$118,727,545
Effect Of Exchange Rate Changes	$313,537	$-577,869	$1,249,571	$-489,759
Changes In Cash	$-15,898,844	$-4,238,471	$-45,080,673	$-21,859,481
Proceeds From Stock Option Exercised	$451,997	$3,350,498	$17,142,694	$226,571
Net Issuance Payments Of Debt	$-2,701,682	$-10,225,426	$-10,196,819	$-2,318,343
Net Long Term Debt Issuance	$-2,701,682	$-10,225,426	$-10,196,819	$-2,318,343
Long Term Debt Payments	$-2,701,682	$-10,225,426	$-10,196,819	$-2,318,343
Interest Received Cfi	$0	$0	$443,987	$0
Net Investment Purchase And Sale	$26,053,324	$10,973,796	$8,050,120	$3,432,887
Sale Of Investment	$26,053,324	$10,973,796	$8,050,120	$3,432,887
Net Intangibles Purchase And Sale	$-2,288,591	$0	$0	$-671,702
Purchase Of Intangibles	$-2,288,591	$0	$0	$-671,702
Net PPE Purchase And Sale	$-230,003	$-447,420	$-160,201	$-612,198
Sale Of PPE	$171,644	$0	$0	$0
Purchase Of PPE	$-401,648	$-447,420	$-160,201	$-612,198
Change In Working Capital	$-36,722,738	$44,812,908	$-12,166,152	$-14,307,129
Other Non Cash Items	$6,866	$-407,369	$-405,081	$152,191
Stock Based Compensation	$4,870,122	$4,513,102	$2,937,407	$4,862,112
Unrealized Gain Loss On Investment Securities	$-1,821,719	$-1,527,635	$-516,077	$1,569,974
Provisionand Write Offof Assets	$-1,105,390	$-335,279	$3,810,505	$960,064
Depreciation Amortization Depletion	$5,825,609	$2,281,726	$1,583,705	$51,956,746
Depreciation And Amortization	$5,825,609	$2,281,726	$1,583,705	$51,956,746
Pension And Employee Benefit Expense	$326,124	$370,752	$-923,447	$417,668
Net Foreign Currency Exchange Gain Loss	$622,497	$-1,012,702	$1,558,531	$-1,043,598
Gain Loss On Sale Of PPE	$537,819	$22,886	$26,319	$0
Net Income From Continuing Operations	$-8,662,318	$-56,609,453	$-56,273,030	$-66,487,013
Issuance Of Debt	-	-	$0	$0
Interest Paid Cff	-	-	$0	$0
Long Term Debt Issuance	-	-	$0	$0
Purchase Of Investment	-	-	$0	$0
Change In Other Working Capital	-	-	-	$-26,813,137
Change In Other Current Liabilities	-	-	-	$26,085,365
Change In Payables And Accrued Expense	-	-	-	$-8,767,594
Change In Payable	-	-	-	$-8,767,594
Change In Account Payable	-	-	-	$-8,767,594
Change In Receivables	-	-	-	$-4,810,619
Changes In Account Receivables	-	-	-	$-4,810,619
Gain Loss On Investment Securities	-	-	-	$-1,043,598

Fetched: 2026-07-17